10:52 AM EST, 02/03/2025 (MT Newswires) -- Alpha Tau Medical ( DRTS ) said Monday the US Food and Drug Administration approved an investigational device exemption supplement for its Alpha DaRT radiation therapy.

The supplement allows for the expansion of the study examining the combination of Alpha DaRT and first-line chemotherapy to include both newly diagnosed metastatic and locally advanced pancreatic cancer patients, increasing the total number of patients to 30 across two cohorts, according to the company.

Shares of Alpha Tau Medical ( DRTS ) were down 1.6% in recent trading.

Price: 3.64, Change: -0.06, Percent Change: -1.62